Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,075 public trials 581 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT04000282

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • City of Hope Site Number : 8400002 Duarte, California, United States
  • Dana Farber Cancer Institute Site Number : 8400003 Boston, Massachusetts, United States
  • Mayo Clinic of Rochester Site Number : 8400005 Rochester, Minnesota, United States
  • UNC Chapel Hill Site Number : 8400006 Chapel Hill, North Carolina, United States
View Trial Details
Completed

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01745588

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
  • Memorial Sloan Kettering West Harrison Harrison, New York, United States
View Trial Details
Completed

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

NCT04018248

Conditions
B Cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • Henry Ford Hospital Detroit, Michigan, United States
  • National Cancer Center Goyang-si, Gyeonggi-do, South Korea
  • Seoul National University Bundang Hospital Seongnam-si, Gyeonggi-do, South Korea
  • Chonnam National University Hwasun Hospital Hwasun, Jeollanam-do, South Korea
View Trial Details
Completed

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

NCT04191616

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Rocky Mountain Cancer Centers Denver Midtown Denver, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Affiliated Oncologists, LLC Chicago Ridge, Illinois, United States
View all 46 locations
View Trial Details
Completed

Familial Dysglobulinemia

NCT02853214

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Dysglobulinemia, +13 more
Locations
  • Service d'Oncologie-Radiothérapie - CHU Pointe-à-Pitre/Abymes Guadeloupe Pointe à Pitre, Guadeloupe, France
  • Service de Médecine Interne-Hématologie, CHU de Fort de France Fort de France Fort-de-France, Martinique, France
  • CHU d'ABBEVILLE Abbeville, France
  • CHU Amiens Picardie Amiens, France
View all 47 locations
View Trial Details
Completed

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

NCT03525678

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site New Haven, Connecticut, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Chicago, Illinois, United States
View all 59 locations
View Trial Details

Related conditions